Comprehensive Psychiatry
Volume 50, Issue 3 , Pages 257-262 , May 2009

The Clinical Global Impressions scale: errors in understanding and use

  • Joan Busner

      Affiliations

    • Department of Psychiatry, Penn State College of Medicine, Hershey, PA, USA
    • United BioSource Corporation, Wayne, PA, USA
    • Corresponding Author InformationCorresponding author. United BioSource Corporation, Wayne, PA 19087, USA. Tel.: +1 610 225 5982.
    • ,
  • Steven D. Targum

      Affiliations

    • United BioSource Corporation, Wayne, PA, USA
    • Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
    • Oxford BioScience Partners, Boston, MA
    • ,
  • David S. Miller

      Affiliations

    • United BioSource Corporation, Wayne, PA, USA

References 

  1. Food and Drug Administration . Guidance for industry: E9 statistical principles for clinical trials. 1998;
  2. Guy W. Clinical global impressions. In:  Guy W editors. ECDEU assessment manual for psychopharmacology (Revised). Rockville (Md): National Institute of Mental Health; 1976;p. 217–221
  3. Guy W, Bonato RR. Clinical global impression. In:  Guy W,  Bonato RR editor. Manual for the ECDEU Assessment Battery. Chevy Chase (Md): National Institute of Mental Health; 1970;
  4. Rapoport J, Conners CK. Clinical global impressions. In:  Rapoport J,  Conners CK editor. Rating scales and assessment instruments for use in pediatric psychopharmacology research (special issue). Psychopharmacol Bull. 21(4):1985;p. 839–843
  5. Beneke M, Rasmus W. Clinical global impressions (ECDEU): some critical comments. Pharmacopsychiatry. 1992;25:171–176
  6. Haro JM, Kamath SA, Ochoa S, et al. The clinical global impression-schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand. 2003;107(Suppl. 416):16–23
  7. Kadouri A, Corruble E, Falissard B. The improved Clinical Global Impression Scale (iCGI): development and validation in depression. BMC Psychiatr. 2007;7:7
  8. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73:159–171
  9. Schmidt ME, Fava M, Shuyu Z, et al. Treatment approaches to major depressive disorder relapse. Psychother Psychosom. 2002;71(4):190–194
  10. Green AI, Tohen MF, Hamer RM, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res. 2004;66:125–135
  11. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396–1404
  12. Kinrys G, Vasconcelos e Sa D, Nery F. Adjunctive zonisamide for treatment refractory anxiety. Int J Clin Pract. 2007;61(6):1050–1053
  13. Physicians' Desk Reference 2007. Montvale (NJ): Thompson PDR; 2007;
  14. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc. 2002;287:1840–1847
  15. Mallinckrodt CH, Meyers AL, Prakash A, Faries DE, Detke MJ. Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull. 2007;40(2):101–114
  16. Khan A, Klots RL, Thase ME, Krishnan KRR, Brown W. Research design features and patient characteristics associated with outcome of antidepressant clinical trials. Am J Psychiatry. 2004;161:2045–2049
  17. Fava M, Evins AE, Dorer DJ, Schoenfeld DA. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72:115–127
  18. Khan A, Schwartz K, Kolts RL, Ridgway D, Lineberry C. Relationship between depression severity entry criteria and antidepressant clinical trial outcomes. Biol Psychiat. 2007;62:65–71
  19. Code of Federal Regulations. Title 21, Food and Drug, Volume 5, Revised as of April 1, 2007, Part 312, Investigational new drug application, subpart D, responsibilities of sponsors and investigators, section 312.50, general responsibilities of sponsors. United States Federal Government.

 Portions of the data were previously presented as posters at the 47th Annual Meeting of the NCDEU, Boca Raton, FL, June 11 to 14, 2007, and the 20th Congress of the European College of Neuropsychopharmacology, October 13 to 17, 2007, Vienna, Austria.

 The authors are all affiliated with United BioSource Corporation (Wayne, PA), which provides rater training services. Dr Targum is an equity holder of United BioSource Corporation.

PII: S0010-440X(08)00117-X

doi: 10.1016/j.comppsych.2008.08.005

Comprehensive Psychiatry
Volume 50, Issue 3 , Pages 257-262 , May 2009

Article Tools

* Image Usage & Resolution